NCT04899180View on ClinicalTrials.gov

Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

January 5, 2024

Study Completion Date

January 5, 2024

Conditions

Aortic StenosisTransthyretin AmyloidosisTransthyretin Amyloid CardiomyopathyTransthyretin Cardiac Amyloidosis

Interventions

DRUG

99mTc-PYP

Radioisotope used by SPECT/CT imaging

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER

NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis | Biotech Hunter | Biotech Hunter